Merck Launches Two Innovative Technologies to Support Couples on Their Fertility Treatment Journey

Food and Healthcare Press Releases Tuesday October 4, 2016 15:15
DARMSTADT, Germany--4 Oct--PRNewswire/InfoQuest
Not intended for U.S. based media
  • Gavi(TM) allows freezing of oocytes and embryos at key stages
  • Geri(TM) medium supports undisturbed embryo growth
  • Launches in line with Merck's healthcare strategy to deliver innovation through best-in-class assets for the benefit of patients

Merck, a leading science and technology company, today announced the launch of two innovative fertility technologies, Gavi(TM) oocyte protocol and Geri(TM) medium. Both products help to improve key steps of assisted reproductive treatment (ART) - an area where laboratory technologies play a vital role for treatment success.

The launches represent the seventh and eighth product launch in 18 months for the Fertility Technologies unit at Merck, demonstrating the company's healthcare strategy to deliver innovation through best-in class assets. Gavi(TM) enables clinics to preserve human egg cells, also called oocytes, and embryos at the main stages of ART, while Geri(TM) medium supports undisturbed cultivation of embryos.

"Undergoing fertility treatment means looking at a lot of individual variables to ensure that everything is done for a successful outcome. During this process, couples want to be assured that their healthcare providers have the right tools at hand to assess those variables and help them make their dream of having a baby become a reality," said Rehan Verjee, Chief Marketing and Strategy Officer at Merck's biopharma business. "With our two new products, we provide laboratories with important instruments that support fertility treatment tailored to the clinic and to the individual needs of patients."

Preserving oocytes or embryos for future in vitro fertilization and embryo transfers by cooling them to deep sub-zero degrees is a key step in the laboratory. Gavi(TM) is the world's first automated instrument for this preservation technique, also called vitrification. With its latest product innovation, Gavi(TM) provides clinicians with added flexibility when taking important treatment decisions with and for their patients.

Geri(TM) medium was developed to help improve another critical factor for successful treatment, embryo cultivation. After fertilization, the embryo needs to grow and develop before it is transferred into a woman's womb. With the single-step culture medium, Merck now provides a way to support undisturbed incubation and optimal embryo development.

Both products, developed and manufactured by Australian fertility technologies company, Genea Biomedx, will be available in Europe, with Gavi(TM) also launching in Canada and additional regions to follow soon. They are commercialized as part of the partnership between Merck and Genea Biomedx that started in 2015.

About Gavi(TM), Geri(TM) and Gems(TM)
Gavi(TM) is the world's first automated vitrification instrument, developed with the aim to achieve a consistent and standardized vitrification process.

Geri(TM) is a benchtop incubator with individually controlled incubation chambers per patient to minimize disruptive events to the early-stage embryo. It also incorporates a time-lapse camera to capture images of embryos as they develop.

Gems(TM) is the latest generation of Genea Biomedx's culture media suite for high-quality embryo cultivation.
Gavi(TM), Geri(TM) and Gems(TM) received the CE mark clearance in Europe, and also the consumables for Gavi(TM) and Geri(TM) are certified. The three devices are not yet cleared for use in the USA.
GaviTM, GeriTM and GemsTM are created by Genea Biomedx.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of EUR 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Contact:
Dr. Raphaela Farrenkopf
+49-6151-72-2274
(Logo: http://photos.prnewswire.com/prnh/20160913/406891LOGO )
(Photo: http://photos.prnewswire.com/prnh/20161003/414692 )
(Photo: http://photos.prnewswire.com/prnh/20161003/414694-INFO )
(Photo: http://photos.prnewswire.com/prnh/20161003/414693 )
Source: Merck

Latest Press Release

Grunenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grunenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza(R) (8 % capsaicin) for...

Ascensia Diabetes Care Highlights the Support That Families Provide for People With Diabetes To Mark World Diabetes Day 2018

Today, Ascensia Diabetes Care, a global leading diabetes care company, launched their campaign for World Diabetes Day 2018 to celebrate the important role of families for people with diabetes. They are publishing 38 online artworks that tell the stories...

Qatar Foundation Ushers in New Era of Healthcare With Official Inauguration of Sidra Medicine

Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation (QF), today officially inaugurated Sidra Medicine - a brand new, world-leading women's and children's hospital in Qatar. The grand opening reflects the country's broader focus and...

Singapore National Eye Centre, Singapore Eye Research Institute And Johnson Johnson Vision Set Sights On Halting Global Myopia Epidemic

New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and Johnson & Johnson Vision today announced a...

TIENS Group Launches Global Expansion Into New Retail

Leading healthcare company, TIENS Group, has announced their global expansion into the new retail market with the opening of a new flagship TIENS Experience Store in China. Located in the TIENS International Health Industrial Park, the new store features...

Related Topics